Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01011894 · ClinicalTrials.gov registry record · Phase 2
Lenalidomide in Patients With Chronic Lymphocytic Leukemia Older Than 65 Years of Age
A Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 26
- Enrollment target
NCT01011894: Completed Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT01011894 is a Phase 2 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 26 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01011894, a Phase 2 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 26 participants
- Enrollment target
Study Summary
The purpose of this study is to: Determine the likelihood that lenalidomide will adequately control the disease for at least one year. Lenalidomide is a drug that alters the immune system and it may also interfere with the development of tiny blood vessels that help support tumor growth. Therefore, in theory, it may reduce or prevent the growth of cancer cells. Lenalidomide is approved by the Food and Drug Administration (FDA) for the treatment of specific types of myelodysplastic syndrome (MDS) and in combination with dexamethasone for patients with multiple myeloma (MM) who have received at least 1 prior therapy. MDS and MM are cancers of the blood. It is currently being tested in a variety of cancer conditions. In this case it is considered experimental. The lenalidomide being administered in this study is not a commercially marketed product. Although it is expected to be very similar in safety and activity to the commercially marketed drug, it is possible that some differences may exist. Because this is not a commercially marketed drug, lenalidomide can only be administered to patients enrolled in this clinical trial and may only be administered under the direction of physicians who are investigators in this clinical trial.
Interventions
- DRUG lenalidomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2009-11-06 |
| Est. Completion | 2016-02-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01011894
The ClinicalTrials.gov registry entry for NCT01011894 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which lenalidomide is the first listed.
NCT01011894 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01011894 about?
NCT01011894 is a clinical study titled "Lenalidomide in Patients With Chronic Lymphocytic Leukemia Older Than 65 Years of Age". The purpose of this study is to: Determine the likelihood that lenalidomide will adequately control the disease for at least one year. Lenalidomide is a drug that alters the immune system and it may also interfere with the development of tiny blood vessels that help support tumor growth. Therefore...
What is the current status of trial NCT01011894?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 26 participants. The study started on 2009-11-06. Estimated completion is 2016-02-23.
What interventions are being tested in trial NCT01011894?
The interventions under investigation include: lenalidomide (DRUG).
Who is sponsoring clinical trial NCT01011894?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.